INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 65 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7 | -75.0% | 34,545 | -80.4% | 0.00% | -66.7% |
| Q1 2023 | $28 | -24.3% | 176,529 | +165.3% | 0.00% | -40.0% |
| Q4 2022 | $37 | -99.7% | 66,537 | +300.0% | 0.01% | +400.0% |
| Q2 2022 | $11,000 | -94.1% | 16,636 | -79.8% | 0.00% | -94.7% |
| Q4 2021 | $185,000 | +54.2% | 82,316 | +134.1% | 0.02% | +72.7% |
| Q3 2021 | $120,000 | -65.2% | 35,166 | -69.5% | 0.01% | -67.6% |
| Q2 2021 | $345,000 | +70.0% | 115,312 | +83.1% | 0.03% | +142.9% |
| Q1 2021 | $203,000 | +1745.5% | 62,984 | +412.8% | 0.01% | +1300.0% |
| Q2 2020 | $11,000 | -59.3% | 12,283 | -55.8% | 0.00% | -66.7% |
| Q4 2019 | $27,000 | +35.0% | 27,796 | +157.6% | 0.00% | +200.0% |
| Q1 2019 | $20,000 | -39.4% | 10,791 | -61.1% | 0.00% | -50.0% |
| Q4 2018 | $33,000 | -77.9% | 27,706 | -60.9% | 0.00% | -75.0% |
| Q1 2018 | $149,000 | +964.3% | 70,854 | +585.3% | 0.01% | +700.0% |
| Q3 2017 | $14,000 | – | 10,339 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |